Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Activating transcription factor 2 in mesenchymal tumors.

Endo M, Su L, Nielsen TO.

Hum Pathol. 2014 Feb;45(2):276-84. doi: 10.1016/j.humpath.2013.09.003. Epub 2013 Nov 27.

PMID:
24289970
2.

Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.

Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S, Poulin N, Yi L, Rossi FM, Kast J, Capecchi MR, Underhill TM, Nielsen TO.

Cancer Cell. 2012 Mar 20;21(3):333-47. doi: 10.1016/j.ccr.2012.01.010.

3.

TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies.

Terry J, Saito T, Subramanian S, Ruttan C, Antonescu CR, Goldblum JR, Downs-Kelly E, Corless CL, Rubin BP, van de Rijn M, Ladanyi M, Nielsen TO.

Am J Surg Pathol. 2007 Feb;31(2):240-6.

PMID:
17255769
4.

Expression of insulin-like growth factor 2 in mesenchymal neoplasms.

Steigen SE, Schaeffer DF, West RB, Nielsen TO.

Mod Pathol. 2009 Jul;22(7):914-21. doi: 10.1038/modpathol.2009.48. Epub 2009 May 1.

5.

SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas.

Jones KB, Su L, Jin H, Lenz C, Randall RL, Underhill TM, Nielsen TO, Sharma S, Capecchi MR.

Oncogene. 2013 May 2;32(18):2365-71, 2375.e1-5. doi: 10.1038/onc.2012.247. Epub 2012 Jul 16.

6.

Immunostaining for SYT protein discriminates synovial sarcoma from other soft tissue tumors: analysis of 146 cases.

He R, Patel RM, Alkan S, Hammadeh R, Weiss SW, Goldblum JR, Venkataraman G, Baila H.

Mod Pathol. 2007 May;20(5):522-8. Epub 2007 Mar 2.

7.

NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.

Lai JP, Robbins PF, Raffeld M, Aung PP, Tsokos M, Rosenberg SA, Miettinen MM, Lee CC.

Mod Pathol. 2012 Jun;25(6):854-8. doi: 10.1038/modpathol.2012.31. Epub 2012 Mar 2.

8.

TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms.

Kosemehmetoglu K, Vrana JA, Folpe AL.

Mod Pathol. 2009 Jul;22(7):872-8. doi: 10.1038/modpathol.2009.47. Epub 2009 Apr 10.

9.

Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation.

Allander SV, Illei PB, Chen Y, Antonescu CR, Bittner M, Ladanyi M, Meltzer PS.

Am J Pathol. 2002 Nov;161(5):1587-95.

10.

The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas: a validation study.

Ito J, Asano N, Kawai A, Yoshida A.

Hum Pathol. 2016 Jan;47(1):32-7. doi: 10.1016/j.humpath.2015.09.010. Epub 2015 Sep 25.

PMID:
26520417
11.

Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics.

Foo WC, Cruise MW, Wick MR, Hornick JL.

Am J Clin Pathol. 2011 Jun;135(6):839-44. doi: 10.1309/AJCP45SSNAOPXYXU.

12.

Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma.

Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO.

Am J Surg Pathol. 2009 Dec;33(12):1743-51. doi: 10.1097/PAS.0b013e3181b7ed36.

PMID:
19809272
13.

Specificity of TLE1 expression in unclassified high-grade sarcomas for the diagnosis of synovial sarcoma.

Valente AL, Tull J, Zhang S.

Appl Immunohistochem Mol Morphol. 2013 Oct;21(5):408-13. doi: 10.1097/PAI.0b013e318279f9ee.

PMID:
23197007
14.

Detection of the synovial sarcoma translocation t(X;18) (SYT;SSX) in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: a reliable and powerful diagnostic tool for pathologists. A molecular analysis of 221 mesenchymal tumors fixed in different fixatives.

Guillou L, Coindre J, Gallagher G, Terrier P, Gebhard S, de Saint Aubain Somerhausen N, Michels J, Jundt G, Vince DR, Collin F, Trassard M, Le Doussal V, Benhattar J.

Hum Pathol. 2001 Jan;32(1):105-12.

PMID:
11172303
15.

Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.

Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL.

Cancer Res. 2003 Dec 1;63(23):8103-7.

16.

Utility of characteristic 'Weak to Absent' INI1/SMARCB1/BAF47 expression in diagnosis of synovial sarcomas.

Rekhi B, Vogel U.

APMIS. 2015 Jul;123(7):618-28. doi: 10.1111/apm.12395. Epub 2015 Apr 24.

PMID:
25912315
17.

Nuclear beta-catenin in mesenchymal tumors.

Ng TL, Gown AM, Barry TS, Cheang MC, Chan AK, Turbin DA, Hsu FD, West RB, Nielsen TO.

Mod Pathol. 2005 Jan;18(1):68-74.

18.

TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases.

Knösel T, Heretsch S, Altendorf-Hofmann A, Richter P, Katenkamp K, Katenkamp D, Berndt A, Petersen I.

Eur J Cancer. 2010 Apr;46(6):1170-6. doi: 10.1016/j.ejca.2010.01.032. Epub 2010 Feb 25.

PMID:
20189377
19.

HMGA proteins in malignant peripheral nerve sheath tumor and synovial sarcoma: preferential expression of HMGA2 in malignant peripheral nerve sheath tumor.

Hui P, Li N, Johnson C, De Wever I, Sciot R, Manfioletti G, Tallini G.

Mod Pathol. 2005 Nov;18(11):1519-26.

20.

Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma.

Amary MF, Berisha F, Bernardi Fdel C, Herbert A, James M, Reis-Filho JS, Fisher C, Nicholson AG, Tirabosco R, Diss TC, Flanagan AM.

Mod Pathol. 2007 Apr;20(4):482-96. Epub 2007 Mar 2.

Items per page

Supplemental Content

Write to the Help Desk